JP6506746B2 - ステアリドン酸及びオリーブ油を含む食用の脂質組成物 - Google Patents
ステアリドン酸及びオリーブ油を含む食用の脂質組成物 Download PDFInfo
- Publication number
- JP6506746B2 JP6506746B2 JP2016521617A JP2016521617A JP6506746B2 JP 6506746 B2 JP6506746 B2 JP 6506746B2 JP 2016521617 A JP2016521617 A JP 2016521617A JP 2016521617 A JP2016521617 A JP 2016521617A JP 6506746 B2 JP6506746 B2 JP 6506746B2
- Authority
- JP
- Japan
- Prior art keywords
- sda
- lipid composition
- oil
- olive oil
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- OPGOLNDOMSBSCW-CLNHMMGSSA-N Fursultiamine hydrochloride Chemical compound Cl.C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N OPGOLNDOMSBSCW-CLNHMMGSSA-N 0.000 title claims description 198
- JIWBIWFOSCKQMA-UHFFFAOYSA-N stearidonic acid Natural products CCC=CCC=CCC=CCC=CCCCCC(O)=O JIWBIWFOSCKQMA-UHFFFAOYSA-N 0.000 title claims description 198
- 150000002632 lipids Chemical class 0.000 title claims description 168
- 239000000203 mixture Substances 0.000 title claims description 167
- 239000004006 olive oil Substances 0.000 title claims description 138
- 235000008390 olive oil Nutrition 0.000 title claims description 136
- 239000003921 oil Substances 0.000 claims description 113
- 235000019198 oils Nutrition 0.000 claims description 112
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 62
- 235000013824 polyphenols Nutrition 0.000 claims description 62
- 238000000034 method Methods 0.000 claims description 22
- 125000004494 ethyl ester group Chemical group 0.000 claims description 20
- 201000001320 Atherosclerosis Diseases 0.000 claims description 15
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 14
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims description 13
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims description 13
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 13
- 229940031439 squalene Drugs 0.000 claims description 13
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims description 13
- 239000010460 hemp oil Substances 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 11
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 10
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 10
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 10
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 10
- 239000005642 Oleic acid Substances 0.000 claims description 10
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 10
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 10
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 235000020778 linoleic acid Nutrition 0.000 claims description 8
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 7
- 201000004681 Psoriasis Diseases 0.000 claims description 7
- 206010003246 arthritis Diseases 0.000 claims description 7
- 208000006673 asthma Diseases 0.000 claims description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 206010011091 Coronary artery thrombosis Diseases 0.000 claims description 5
- 208000001132 Osteoporosis Diseases 0.000 claims description 5
- 208000002528 coronary thrombosis Diseases 0.000 claims description 5
- 230000009467 reduction Effects 0.000 claims description 5
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 202
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 125
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 125
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 125
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 125
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 104
- 229940090949 docosahexaenoic acid Drugs 0.000 description 101
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 37
- 238000006243 chemical reaction Methods 0.000 description 23
- 229940012843 omega-3 fatty acid Drugs 0.000 description 22
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 20
- 230000003647 oxidation Effects 0.000 description 18
- 238000007254 oxidation reaction Methods 0.000 description 18
- 235000021323 fish oil Nutrition 0.000 description 16
- 239000006014 omega-3 oil Substances 0.000 description 15
- JUUBCHWRXWPFFH-UHFFFAOYSA-N Hydroxytyrosol Chemical compound OCCC1=CC=C(O)C(O)=C1 JUUBCHWRXWPFFH-UHFFFAOYSA-N 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 239000012141 concentrate Substances 0.000 description 13
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 12
- 102000007330 LDL Lipoproteins Human genes 0.000 description 10
- 108010007622 LDL Lipoproteins Proteins 0.000 description 10
- 235000013305 food Nutrition 0.000 description 10
- 229960004488 linolenic acid Drugs 0.000 description 10
- 235000014113 dietary fatty acids Nutrition 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000003925 fat Substances 0.000 description 9
- 229930195729 fatty acid Natural products 0.000 description 9
- 239000000194 fatty acid Substances 0.000 description 9
- 150000004665 fatty acids Chemical class 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 235000015112 vegetable and seed oil Nutrition 0.000 description 9
- 230000003078 antioxidant effect Effects 0.000 description 8
- 235000019197 fats Nutrition 0.000 description 8
- 230000036541 health Effects 0.000 description 8
- 210000002433 mononuclear leukocyte Anatomy 0.000 description 8
- 150000003626 triacylglycerols Chemical class 0.000 description 8
- 239000008158 vegetable oil Substances 0.000 description 8
- 241000251468 Actinopterygii Species 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 7
- 241000282412 Homo Species 0.000 description 7
- 239000003963 antioxidant agent Substances 0.000 description 7
- 235000006708 antioxidants Nutrition 0.000 description 7
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 7
- 235000019688 fish Nutrition 0.000 description 7
- 150000004668 long chain fatty acids Chemical class 0.000 description 7
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 7
- 230000001590 oxidative effect Effects 0.000 description 7
- 230000036542 oxidative stress Effects 0.000 description 7
- YCCILVSKPBXVIP-UHFFFAOYSA-N 2-(4-hydroxyphenyl)ethanol Chemical compound OCCC1=CC=C(O)C=C1 YCCILVSKPBXVIP-UHFFFAOYSA-N 0.000 description 6
- 102000015779 HDL Lipoproteins Human genes 0.000 description 6
- 108010010234 HDL Lipoproteins Proteins 0.000 description 6
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 6
- 235000003248 hydroxytyrosol Nutrition 0.000 description 6
- 229940095066 hydroxytyrosol Drugs 0.000 description 6
- 229940033080 omega-6 fatty acid Drugs 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 5
- 238000008214 LDL Cholesterol Methods 0.000 description 5
- 208000029078 coronary artery disease Diseases 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 5
- 208000027866 inflammatory disease Diseases 0.000 description 5
- 238000012423 maintenance Methods 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- 108010028554 LDL Cholesterol Proteins 0.000 description 4
- 240000007817 Olea europaea Species 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 235000020667 long-chain omega-3 fatty acid Nutrition 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 3
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 3
- 244000025254 Cannabis sativa Species 0.000 description 3
- 241001071905 Echium Species 0.000 description 3
- 230000003143 atherosclerotic effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 235000019219 chocolate Nutrition 0.000 description 3
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 3
- 239000010462 extra virgin olive oil Substances 0.000 description 3
- 235000021010 extra-virgin olive oil Nutrition 0.000 description 3
- 235000021588 free fatty acids Nutrition 0.000 description 3
- 230000005802 health problem Effects 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 150000002989 phenols Chemical class 0.000 description 3
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 3
- 230000007115 recruitment Effects 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 239000010463 virgin olive oil Substances 0.000 description 3
- RFWGABANNQMHMZ-UHFFFAOYSA-N 8-acetoxy-7-acetyl-6,7,7a,8-tetrahydro-5H-benzo[g][1,3]dioxolo[4',5':4,5]benzo[1,2,3-de]quinoline Natural products CC=C1C(CC(=O)OCCC=2C=C(O)C(O)=CC=2)C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O RFWGABANNQMHMZ-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
- HKVGJQVJNQRJPO-UHFFFAOYSA-N Demethyloleuropein Natural products O1C=C(C(O)=O)C(CC(=O)OCCC=2C=C(O)C(O)=CC=2)C(=CC)C1OC1OC(CO)C(O)C(O)C1O HKVGJQVJNQRJPO-UHFFFAOYSA-N 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- DBLDQZASZZMNSL-QMMMGPOBSA-N L-tyrosinol Natural products OC[C@@H](N)CC1=CC=C(O)C=C1 DBLDQZASZZMNSL-QMMMGPOBSA-N 0.000 description 2
- 241000207836 Olea <angiosperm> Species 0.000 description 2
- RFWGABANNQMHMZ-HYYSZPHDSA-N Oleuropein Chemical compound O([C@@H]1OC=C([C@H](C1=CC)CC(=O)OCCC=1C=C(O)C(O)=CC=1)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RFWGABANNQMHMZ-HYYSZPHDSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 2
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 230000036523 atherogenesis Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 230000005189 cardiac health Effects 0.000 description 2
- 230000036996 cardiovascular health Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 238000003255 drug test Methods 0.000 description 2
- 239000008157 edible vegetable oil Substances 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 235000013332 fish product Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 230000008821 health effect Effects 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000008774 maternal effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 235000011576 oleuropein Nutrition 0.000 description 2
- RFWGABANNQMHMZ-CARRXEGNSA-N oleuropein Natural products COC(=O)C1=CO[C@@H](O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O)C(=CC)[C@H]1CC(=O)OCCc3ccc(O)c(O)c3 RFWGABANNQMHMZ-CARRXEGNSA-N 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 238000009790 rate-determining step (RDS) Methods 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 235000004330 tyrosol Nutrition 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- YUFFSWGQGVEMMI-UHFFFAOYSA-N (7Z,10Z,13Z,16Z,19Z)-7,10,13,16,19-docosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCCCC(O)=O YUFFSWGQGVEMMI-UHFFFAOYSA-N 0.000 description 1
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 description 1
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 235000008697 Cannabis sativa Nutrition 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 235000001412 Mediterranean diet Nutrition 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 235000002725 Olea europaea Nutrition 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 235000021068 Western diet Nutrition 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- -1 at least 95% lipid Chemical class 0.000 description 1
- 230000000923 atherogenic effect Effects 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 235000015496 breakfast cereal Nutrition 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- 229930003827 cannabinoid Natural products 0.000 description 1
- 239000003557 cannabinoid Substances 0.000 description 1
- 229940065144 cannabinoids Drugs 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- XIVFQYWMMJWUCD-UHFFFAOYSA-N dihydrophaseic acid Natural products C1C(O)CC2(C)OCC1(C)C2(O)C=CC(C)=CC(O)=O XIVFQYWMMJWUCD-UHFFFAOYSA-N 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000006203 ethylation Effects 0.000 description 1
- 238000006200 ethylation reaction Methods 0.000 description 1
- 230000004373 eye development Effects 0.000 description 1
- 235000020988 fatty fish Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 210000000497 foam cell Anatomy 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 1
- 229960002733 gamolenic acid Drugs 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000011487 hemp Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 229940060184 oil ingredients Drugs 0.000 description 1
- 235000021315 omega 9 monounsaturated fatty acids Nutrition 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000007112 pro inflammatory response Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000004218 vascular function Effects 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 235000008924 yoghurt drink Nutrition 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
- A23D9/007—Other edible oils or fats, e.g. shortenings, cooking oils characterised by ingredients other than fatty acid triglycerides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
- A23D9/007—Other edible oils or fats, e.g. shortenings, cooking oils characterised by ingredients other than fatty acid triglycerides
- A23D9/013—Other fatty acid esters, e.g. phosphatides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/306—Foods, ingredients or supplements having a functional effect on health having an effect on bone mass, e.g. osteoporosis prevention
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/31—Foods, ingredients or supplements having a functional effect on health having an effect on comfort perception and well-being
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/326—Foods, ingredients or supplements having a functional effect on health having effect on cardiovascular health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
Description
本発明をさらに詳細に議論する前に、以下の用語及び従来技法を最初に定義する。
本発明に記載の脂質組成物は、食用である。食用とは、脂質組成物が吸収に適していることを意味する。したがって、食用の脂質組成物は、病気にならずに及び/又は内部器官を侵さずに動物又は人が摂食するのに適した組成物である。
本発明に記載の脂質組成物は、以下SDA成分と呼ばれるステアリドン酸成分を含む。本発明に記載のSDA成分は、少なくとも6重量%の量のステアリドン酸(SDA)を含む。
-DHA及びEPAは心臓の正常な機能に寄与する(日当り0.25g)
-DHA及びEPAは正常な血圧の維持に寄与する(日当り3g)
-DHA及びEPAは正常な血中トリグリセリドの維持に寄与する(日当り2g)
-DHAは正常な血中トリグリセリドレベルの維持に寄与する(EPAと組み合わせて日当り2g)
-DHAは正常な脳機能の維持に寄与する(日当り0.25g)
-DHAは正常な視覚の維持に寄与する(日当り0.25g)
-DHAの母体摂取は胎児及び母乳で育てた乳幼児の正常な脳の発達に寄与する(DHA0.2gプラス日当り0.25gとされる成人に対するω-3脂肪酸(EPA及びDHA)の日当りの推奨摂取量)
-DHAの母体摂取は胎児及び母乳で育てた乳幼児の正常な眼の発達に寄与する(DHA0.2gプラス日当り0.25gとされる成人に対するω-3脂肪酸(EPA及びDHA)の日当りの推奨摂取量)。
本発明は、オリーブ油を含む。
本発明に記載の食用の脂質組成物は、一実施形態において、1種以上のさらなる油を含むことができる。一部の場合、SDAからEPA及びDHAへの変換は、十分でない場合があり、次いで、EPA及び/又はDHAを含むさらなる油を脂質組成物に含ませることによって、脂質組成物から変換されたEPA及びDHAの量を、健康効果を有するために、即ち、心血管疾患の発症リスクを低減するために当局が作成したEPA及びDHAの推奨値を満足させることができる。
-毎日2gのDHA及びEPAの摂取は、正常な血中トリグリセリド濃度の維持に寄与する。しかし、日当り最大5gのEPA及びDHAが推奨される。
-毎日3gのDHA及びEPAの摂取は、正常な血圧の維持に寄与する。しかし、日当り最大5gのEPA及びDHAが推奨される。
さらなる油は、藻類油であってよく、本発明の一実施形態では、さらなる油は、藻類油である。藻類油は、DHA又はEPAに富む植物源である。SDAから変換できるものより大きなEPAへの必要性が存在する場合、藻類油は、本発明に記載の脂質組成物中のオリーブ油及びSDA成分と組み合わせて使用するのに有利である。藻類油は、魚又は大豆製品を避けたい人達にとって理想的な代替品である。オリーブ油及びSDA成分を含む脂質組成物に藻類油を添加することによって、脂質組成物は、魚油に対する代替品として完全栄養物になる。その理由は、藻類油は、脂質組成物がEPA及びDHAの推奨値を満足するように、藻類油がEPA又はDHAを追加してくれるからである。しかし、純藻類油は、魚油に対する代替品でない。その理由は、EPA又はDHAいずれかを含有し、その組合せを含むのではないからである。したがって、藻類油は、添加剤として適切であるのみであり、完全栄養物ではない。
さらなる油は、EPA及び/又はDHAのエチルエステルであってよい。EPA及びDHAのエチルエステルは、すぐ吸収される状態にあるすでに消化された脂肪酸である。したがって、EPA及び/又はDHAのエチルエステルは、ω-3脂肪酸の工業源である。
本発明に記載の脂質組成物を調製する方法は、少なくとも250mg/kgの量のポリフェノールを含むオリーブ油と、少なくともSDA6%を含むSDA成分と、任意選択でさらなる油とを混合するステップを含み、オリーブ油とSDA成分の間の比が3:8〜3:2である。油成分のブレンディングは、最適なω-3及び酸化に対する保護を実現するために実施される。オリーブ油とSDA成分の混合は、標準化された油ブレンディング手順によって行われる。
本発明に記載の食用の脂質組成物は、オリーブ油と組み合わせて高量のω-3脂肪酸ステアリドン酸(SDA)を含み、オリーブ油は、SDAの身体中への吸収、したがって、SDAのEPA及びDHAへの変換を増加させる。
SDA油及びオリーブ油を含む組成物
以下の表で、本発明に記載の多様な脂質組成物を示す。脂質組成物はすべて、SDA油及びオリーブ油を含む。
SDA濃縮物及びオリーブ油を含む組成物
以下の表に、SDA濃縮物及びオリーブ油を含む本発明に記載の多様な脂質組成物を示す。
脂質組成物におけるSDA、EPA、DHA及びポリフェノールの量
上の実施例1及び2のA、B、F及びGに記載の脂質組成物中で、SDA及びポリフェノール含量が、測定され、以下の表5で与えられる。さらに、SDAから変換されたEPA、DHA及びDPAを示す。
SDA油とオリーブ油の間の多様な比の比較
上の実施例1又は2に記載したのと同様に多様な脂質組成物を調製し、SDA25%を含むSDA油及びポリフェノール400mg/kgを含むオリーブ油を使用したが、SDA油とオリーブ油の間の比が変動する。
SDA油中に存在する多様な量のSDAの比較
上の実施例1又は2に記載したのと同様に、SDA油50%及びポリフェノール400mg/kgを含むオリーブ油50%を有し、SDA油中のSDA量が変動する多様な脂質組成物を調製した。以下の表7に、多様な脂質組成物中のSDA油の量、存在するSDAの量、及びオリーブ油の量を示す。さらに、SDAの変換後に脂質組成物によって得られるEPA及びDHAを示す。また、脂質組成物中のポリフェノール含量を示す。
オリーブ油中に存在するポリフェノールの多様な量の比較
SDA含量が25%であるSDA油50%及びオリーブ油50%を含む多様な脂質組成物を調製した。上の実施例1又は2に記載したのと同様に組成物を調製した。以下の表8に、多様な脂質組成物中のSDA油及びオリーブ油の量を示す。さらに、使用した脂質組成物中のポリフェノール含量を示す。さらに、SDAの変換後に脂質組成物によって得られたEPA及びDHAを示す。また、脂質組成物中のポリフェノール含量を示す。
本発明に記載の多様な脂質組成物の比較
オリーブ油50%、多様な量のSDA油(30%又は40%)、及び多様な量の藻類油を含み、SDA油がSDA25%を含む多様な脂質組成物を調製した。上の実施例1又は2に記載したのと同様に組成物を調製した。以下の表9に、多様な脂質組成物中のSDA油及びオリーブ油の量を示す。さらに、脂質組成物中のポリフェノール含量を示す。さらに、SDAの変換後に脂質組成物によって得られるEPA及びDHAを示す。オリーブ油中のポリフェノールの量は、400mg/kgである。
ポリフェノールを含むオリーブ油の酸化安定性試験
ポリフェノールを含むオリーブ油の長鎖脂肪酸の酸化ストレスに及ぼす効果を分析した。
A)ω-3脂肪酸を含む油及びビタミンEを含む1つの油ミックス、並びに
B)ポリフェノール含量が400mg/kgであるオリーブ油と組み合わせてω-3脂肪酸を含むa)と同じ油を含む第2の油ミックス
の2つの油ミックスを作製した。
本発明の実施形態として例えば以下を挙げることができる。
[実施形態1]
オリーブ油及びステアリドン酸成分(SDA成分)を含む食用の脂質組成物であって、前記SDA成分が少なくとも6重量%の量のステアリドン酸(SDA)を含み、前記オリーブ油がオリーブ油kg当り少なくとも250mgの量のポリフェノールを含み、オリーブ油とSDA成分の間の比が3:8〜3:2である、食用の脂質組成物。
[実施形態2]
1種以上のさらなる油を含む、実施形態1に記載の食用の脂質組成物。
[実施形態3]
さらなる油が、藻類油又はEPA及び/若しくはDHAのエチルエステルである、実施形態2に記載の食用の脂質組成物。
[実施形態4]
オリーブ油が少なくとも25%の量で存在する、実施形態1から3のいずれかに記載の食用の脂質組成物。
[実施形態5]
SDA成分が少なくとも30重量%の量で存在する、実施形態1から4のいずれかに記載の食用の脂質組成物。
[実施形態6]
SDA成分が少なくとも10重量%の量のSDAを含む、実施形態1から5のいずれかに記載の食用の脂質組成物。
[実施形態7]
脂質組成物100ml当り少なくともSDA3gの量のSDAを含む、実施形態1から6のいずれかに記載の食用の脂質組成物。
[実施形態8]
SDA成分が少なくとも5重量%の量のGLAを含む、実施形態1から7のいずれかに記載の食用の脂質組成物。
[実施形態9]
SDA成分が10重量%未満の量のリノール酸(LA)を含む、実施形態1から8のいずれかに記載の食用の脂質組成物。
[実施形態10]
少なくとも10重量%の量のオレイン酸を含む、実施形態1から9のいずれかに記載の食用の脂質組成物。
[実施形態11]
オリーブ油が0.025〜1重量%の範囲でポリフェノールを含む、実施形態1から10のいずれかに記載の食用の脂質組成物。
[実施形態12]
オリーブ油が少なくとも200mg/kgの量のスクワレンを含む、実施形態1から11のいずれかに記載の食用の脂質組成物。
[実施形態13]
SDA成分が麻実油でない、実施形態1から12のいずれかに記載の食用の脂質組成物。
[実施形態14]
実施形態1〜13のいずれかに記載の脂質組成物を調製する方法であって、オリーブ油kg当り少なくとも250mgの量のポリフェノールを含むオリーブ油と、少なくとも6%のステアリドン酸を含むSDA成分と、任意選択でさらなる油とを混合するステップを含む方法。
[実施形態15]
心血管疾患、冠状動脈血栓症、アテローム性動脈硬化症、ガン、糖尿病、リウマチ、アルツハイマー、関節炎、リウマチ、骨そしょう症、乾癬又はぜんそくの発症リスクの予防又は低減のために動物又はヒトに投与するのに使用するための、実施形態1〜13のいずれかに記載の食用の脂質組成物。
Claims (13)
- オリーブ油及びステアリドン酸成分(SDA成分)を含む食用の脂質組成物であって、前記SDA成分が少なくとも6重量%の量のステアリドン酸(SDA)を含み、前記オリーブ油がオリーブ油kg当り少なくとも250mgの量のポリフェノールを含み、オリーブ油とSDA成分の間の比が3:8〜3:2であり、
オリーブ油が少なくとも25重量%の量で存在し、SDA成分が少なくとも30重量%の量で存在する、食用の脂質組成物。 - 1種以上のさらなる油を含む、請求項1に記載の食用の脂質組成物。
- さらなる油が、藻類油又はEPA及び/若しくはDHAのエチルエステルである、請求項2に記載の食用の脂質組成物。
- SDA成分が少なくとも10重量%の量のSDAを含む、請求項1から3のいずれかに記載の食用の脂質組成物。
- 脂質組成物100ml当り少なくともSDA3gの量のSDAを含む、請求項1から4のいずれかに記載の食用の脂質組成物。
- SDA成分が少なくとも5重量%の量のGLAを含む、請求項1から5のいずれかに記載の食用の脂質組成物。
- SDA成分が10重量%未満の量のリノール酸(LA)を含む、請求項1から6のいずれかに記載の食用の脂質組成物。
- 少なくとも10重量%の量のオレイン酸を含む、請求項1から7のいずれかに記載の食用の脂質組成物。
- オリーブ油が0.025〜1重量%の範囲でポリフェノールを含む、請求項1から8のいずれかに記載の食用の脂質組成物。
- オリーブ油が少なくとも200mg/kgの量のスクワレンを含む、請求項1から9のいずれかに記載の食用の脂質組成物。
- SDA成分が麻実油でない、請求項1から10のいずれかに記載の食用の脂質組成物。
- 請求項1〜11のいずれかに記載の脂質組成物を調製する方法であって、オリーブ油kg当り少なくとも250mgの量のポリフェノールを含むオリーブ油と、少なくとも6%のステアリドン酸を含むSDA成分と、任意選択でさらなる油とを混合するステップを含む方法。
- 心血管疾患、冠状動脈血栓症、アテローム性動脈硬化症、ガン、糖尿病、リウマチ、アルツハイマー、関節炎、骨そしょう症、乾癬又はぜんそくの発症リスクの予防又は低減のために動物又はヒトに投与するのに使用するための、請求項1〜11のいずれかに記載の食用の脂質組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13187560.1 | 2013-10-07 | ||
EP13187560 | 2013-10-07 | ||
PCT/EP2014/071418 WO2015052171A1 (en) | 2013-10-07 | 2014-10-07 | Edible lipid composition comprising stearidonic acid and olive oil |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016533716A JP2016533716A (ja) | 2016-11-04 |
JP6506746B2 true JP6506746B2 (ja) | 2019-04-24 |
Family
ID=49301375
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016521617A Active JP6506746B2 (ja) | 2013-10-07 | 2014-10-07 | ステアリドン酸及びオリーブ油を含む食用の脂質組成物 |
Country Status (15)
Country | Link |
---|---|
US (1) | US20160227808A1 (ja) |
EP (1) | EP3054777B1 (ja) |
JP (1) | JP6506746B2 (ja) |
KR (1) | KR102373207B1 (ja) |
CN (1) | CN105705025B (ja) |
AU (1) | AU2014333878B2 (ja) |
CA (1) | CA2924265C (ja) |
DK (1) | DK3054777T3 (ja) |
EA (1) | EA028641B1 (ja) |
ES (1) | ES2672313T3 (ja) |
HU (1) | HUE037991T2 (ja) |
LT (1) | LT3054777T (ja) |
NO (1) | NO3054777T3 (ja) |
PL (1) | PL3054777T3 (ja) |
WO (1) | WO2015052171A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10846257B2 (en) | 2014-04-01 | 2020-11-24 | Endance Technology Limited | Intelligent load balancing and high speed intelligent network recorders |
CN108402466A (zh) * | 2017-02-10 | 2018-08-17 | 台湾原生药用植物股份有限公司 | 含不饱和脂肪酸的素食组合物 |
JP6901274B2 (ja) * | 2017-02-14 | 2021-07-14 | 株式会社ファンケル | ω3系脂肪酸吸収促進用組成物 |
CA3054478A1 (en) * | 2017-02-28 | 2018-09-07 | Cg-Bio Genomics, Inc. | Composition comprising amino acids, fulvic acids and minerals, and uses thereof as a supplement food |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2150741A1 (en) * | 1994-06-17 | 1995-12-18 | Susan Trimbo | Pediatric lipid emulsion |
WO1997001968A1 (en) * | 1995-07-04 | 1997-01-23 | Suntory Limited | FOOD COMPOSITION CONTAINING BALANCING AGENT FOR φ-6 AND φ-3 UNSATURATED FATTY ACIDS |
JP3466014B2 (ja) * | 1995-12-25 | 2003-11-10 | 交洋ファインケミカル株式会社 | 植物性スクワラン濃縮物の製造方法 |
JP2000104092A (ja) * | 1998-09-29 | 2000-04-11 | Nof Corp | 血清脂質改善油脂組成物 |
JP2007056181A (ja) * | 2005-08-26 | 2007-03-08 | Toyo Olive Co Ltd | 機能性オリーブ油、その製造方法およびその用途 |
JP4904751B2 (ja) * | 2005-09-14 | 2012-03-28 | 株式会社カネカ | 生体内dha合成促進剤 |
ES2289897B1 (es) * | 2005-11-08 | 2008-12-16 | Laboratorios Belmac, S.A. | Composicion para administracion transdermica de agentes fisiologicamente activos. |
CN101437508A (zh) * | 2006-03-03 | 2009-05-20 | 孟山都技术有限公司 | 用于改善心血管健康的十八碳四烯酸 |
KR101502636B1 (ko) * | 2007-01-03 | 2015-03-13 | 몬산토 테크놀로지 엘엘씨 | 스테아리도닉 산이 혼입된 식품 조성물 |
US20090099261A1 (en) * | 2007-09-25 | 2009-04-16 | Isi Brands Inc. | Omega-3 mixtures |
EP2448431A4 (en) * | 2009-06-30 | 2014-12-31 | Solae Llc | BARRIER COMPOSITIONS AND OVEN-COOKED FOOD ENRICHED WITH OMEGA-3 FATTY ACID |
FR2948025B1 (fr) * | 2009-07-15 | 2013-01-11 | Univ Grenoble 1 | Composition comprenant un polyphenol et un acide gras omega-3 |
US20120231142A1 (en) * | 2009-07-15 | 2012-09-13 | Solae, Llc | Omega-3 Fatty Acid Enriched Soups and Sauces |
US8372465B2 (en) * | 2010-02-17 | 2013-02-12 | Bunge Oils, Inc. | Oil compositions of stearidonic acid |
AU2012100994A4 (en) * | 2012-06-30 | 2012-07-26 | Hinson, Brian Mr | Hempseed/olive oil and waste blending |
-
2014
- 2014-10-07 CA CA2924265A patent/CA2924265C/en active Active
- 2014-10-07 CN CN201480055348.9A patent/CN105705025B/zh active Active
- 2014-10-07 US US15/026,266 patent/US20160227808A1/en not_active Abandoned
- 2014-10-07 DK DK14781196.2T patent/DK3054777T3/en active
- 2014-10-07 AU AU2014333878A patent/AU2014333878B2/en active Active
- 2014-10-07 KR KR1020167010874A patent/KR102373207B1/ko active IP Right Grant
- 2014-10-07 EP EP14781196.2A patent/EP3054777B1/en active Active
- 2014-10-07 NO NO14781196A patent/NO3054777T3/no unknown
- 2014-10-07 ES ES14781196.2T patent/ES2672313T3/es active Active
- 2014-10-07 PL PL14781196T patent/PL3054777T3/pl unknown
- 2014-10-07 HU HUE14781196A patent/HUE037991T2/hu unknown
- 2014-10-07 WO PCT/EP2014/071418 patent/WO2015052171A1/en active Application Filing
- 2014-10-07 EA EA201690692A patent/EA028641B1/ru not_active IP Right Cessation
- 2014-10-07 JP JP2016521617A patent/JP6506746B2/ja active Active
- 2014-10-07 LT LTEP14781196.2T patent/LT3054777T/lt unknown
Also Published As
Publication number | Publication date |
---|---|
EP3054777B1 (en) | 2018-03-07 |
EP3054777A1 (en) | 2016-08-17 |
ES2672313T3 (es) | 2018-06-13 |
AU2014333878B2 (en) | 2017-12-07 |
HUE037991T2 (hu) | 2018-09-28 |
AU2014333878A1 (en) | 2016-04-14 |
PL3054777T3 (pl) | 2018-10-31 |
KR20160065903A (ko) | 2016-06-09 |
KR102373207B1 (ko) | 2022-03-11 |
CA2924265A1 (en) | 2015-04-16 |
NO3054777T3 (ja) | 2018-08-04 |
LT3054777T (lt) | 2018-07-10 |
JP2016533716A (ja) | 2016-11-04 |
CN105705025A (zh) | 2016-06-22 |
AU2014333878A2 (en) | 2016-04-21 |
EA201690692A1 (ru) | 2016-07-29 |
WO2015052171A1 (en) | 2015-04-16 |
CN105705025B (zh) | 2020-06-23 |
EA028641B1 (ru) | 2017-12-29 |
CA2924265C (en) | 2019-12-24 |
US20160227808A1 (en) | 2016-08-11 |
DK3054777T3 (en) | 2018-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ganesan et al. | Impact of consumption and cooking manners of vegetable oils on cardiovascular diseases-A critical review | |
Stuchlík et al. | Vegetable lipids as components of functional foods | |
Chen et al. | Design of foods with bioactive lipids for improved health | |
CA2694054C (en) | Omega-3 fatty acid fortified composition | |
Carandang | Health benefits of virgin coconut oil | |
Guo et al. | The relationship between lipid phytochemicals, obesity and its related chronic diseases | |
US8507466B2 (en) | Oils enriched with diacylglycerols and phytosterol esters and unit dosage forms thereof for use in therapy | |
US20070213395A1 (en) | Dietary supplement composition for blood lipid health | |
US20060052351A1 (en) | Oils enriched with diacylglycerols and phytosterol esters for use in the reduction of blood cholestrol and triglycerides and oxidative stress | |
JP6506746B2 (ja) | ステアリドン酸及びオリーブ油を含む食用の脂質組成物 | |
Aluko et al. | Bioactive lipids | |
de Lorgeril et al. | Dietary prevention of coronary heart disease: the Lyon diet heart study and after | |
Malik et al. | Dietary Lipids and Health | |
Kengne et al. | Investigation of the antihyperlipidemic property of Raphia hookeri mesocarp oil in high-lard diet (HLD) fed rats | |
Ghanbari Shendi | Olive oil: nutraceutical and pharmaceutical food | |
Chandra et al. | Health benefits of sesame oil on hypertension and atherosclerosis | |
ES2413497A1 (es) | Composición con alto contenido en Omega 3, Omega 6 y Omega 9 | |
Block et al. | 5 Soybean Oil | |
Shahidi et al. | Dietary Lipid Supplements | |
Waly | Mediterranean foods and human health | |
Lipnik-Stangelj et al. | Olive tree-the source of pharmacodynamically active substances | |
Bhattacharya et al. | Dietary fats and age-related diseases | |
BEARE‐ROGERS | Dietary fatty acids, where are we going? | |
Misner | Fish Oil's Benefits Defended |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20160914 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20160914 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170413 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180223 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180306 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180606 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180904 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20181122 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190220 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190305 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190329 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6506746 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |